In addition to SHP2 and MEK inhibitors, many other drugs have been developed in the field of oncology for the treatment of cancers driven by alterations in the RAS/MAPK pathway and could potentially be used for the treatment of RASopathies. Here, MAP2K7 is linked to RASopathy.